BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Seminar by Dr. Francesco de Rubertis\, MedicXi // Venture capital 
 investing in early stage life sciences
DTSTART:20190402T160000
DTEND:20190402T174500
DTSTAMP:20260502T073017Z
UID:847ac49d6f9f1ea75b7a6af5c08bd885cec0dd7292c3be73bc5df4ce
CATEGORIES:Conferences - Seminars
DESCRIPTION:Fransesco De Rubertis\nLearn how a Venture Capital can fund an
 d support high potential scientists and early translational technologies\,
  on their path towards development.\n\nThe seminar by Dr. Francesco de Rub
 ertis will be followed by 1-on-1 workshop with Francesco\, and probably ot
 her Industry experts\, where EPFL  members can pitch their translational 
 project (on Doodle registration until  25.03.2019 at https://epfl.doodle
 .com/poll/k2pyewrz4q9p74md)\n\nThis seminar is in the frame of  the 1st C
 4L Translational Innovation Evening\; A bi-monthly series of informal even
 ts where researchers of the EPFL School of Life Sciences can pitch and dis
 cuss their early stage translational project with senior industry experts.
 \n\nMedicXi is a Venture Capital firm\,  equally comfortable to invest at
  a very early-stage of drug development\, when candidate drugs have just b
 een discovered and are entering preclinical stage\, as at later stages of 
 clinical development.\n\nFrancesco is a co-founder and Partner at Medicxi.
  Prior to Medicxi\, Francesco was a partner at Index Ventures for 19 years
 \, having joined the firm in 1997 to launch its life sciences practice. Un
 der his leadership\, the asset-centric approach to life sciences investing
  was conceived and adopted. Francesco currently serves on the boards of a 
 number of portfolio companies\, including Janpix and Critical Pressure. 
   Francesco’s prior investments include CellZome (acquired by GlaxoSmit
 hKline)\, GenMab (Copenhagen: GEN.CO)\, GenSight Biologics (Euronext: SIGH
 T)\, Micromet (acquired by Amgen)\, Minerva Neurosciences (NASDAQ:NERV)\, 
 Molecular Partners (Swiss:MOLN.SW)\, PanGenetics (acquired by Abbott)\, Pa
 rallele Biosciences (acquired by Affymetrix)\, Profibrix (acquired by The 
 Medicines Company)\, Versartis (NASDAQ:VSAR). Francesco received a BA in G
 enetics and Microbiology from the University of Pavia and a PhD Molecular 
 Biology from the University of Geneva. He conducted postdoctoral research 
 at the Whitehead Institute at MIT and is a CFA Charterholder. Francesco al
 so serves on the strategic advisory board of the University of Geneva.\n 
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR